Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity

Phenotype molding of stromal cells in the lung tumor microenvironment

(2018) Diether Lambrechts et al.   NATURE MEDICINE

Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking

(2018) Alessandro Porrello et al.   Nature Communications

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

(2017) Esra A. Akbay et al.   Journal of Thoracic Oncology

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

(2017) Stephen J. Bagley et al.   LUNG CANCER

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment

(2017) Susanne M. Steggerda et al.   Journal for ImmunoTherapy of Cancer

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment

(2017) Michael R. Cassidy et al.   EBioMedicine

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer

(2016) M. S. Caetano et al.   CANCER RESEARCH

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

(2016) D. Morgensztern et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic communication in tumors: a new layer of immunoregulation for immune evasion

(2016) Ping-Chih Ho et al.   Journal for ImmunoTherapy of Cancer

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity

(2015) F. Mussai et al.   CANCER RESEARCH

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

IDO inhibitors move center stage in immuno-oncology

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells

(2015) Laura J Pallett et al.   NATURE MEDICINE

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Deletion of cyclooxygenase-2 inhibits K-ras–induced lung carcinogenesis

(2015) Yong Pan et al.   Oncotarget

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

T helper 17 cells play a critical pathogenic role in lung cancer

(2014) S. H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Functions of Arginase Isoforms in Macrophage Inflammatory Responses: Impact on Cardiovascular Diseases and Metabolic Disorders

(2014) Zhihong Yang et al.   Frontiers in Immunology

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

(2013) F. Mussai et al.   BLOOD

The Emerging "Hallmarks" of Metabolic Reprogramming and Immune Evasion: Distinct or Linked?

(2013) I. Kareva et al.   CANCER RESEARCH

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

(2013) David Vasquez-Dunddel et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury

(2013) Michael C. Van Zandt et al.   JOURNAL OF MEDICINAL CHEMISTRY

Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients

(2013) Marlies E. Heuvers et al.   LUNG CANCER

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction

(2013) Jochen Steppan et al.   Frontiers in Immunology

Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer

(2013) Robert Wesolowski et al.   Journal for ImmunoTherapy of Cancer

Therapeutic Implications of KIT in Melanoma

(2012) Michael A. Postow et al.   CANCER JOURNAL

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

IL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer

(2011) Kevin M. Hart et al.   Frontiers in Immunology

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

(2010) Cesar A. Corzo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

(2010) Cole Trapnell et al.   NATURE BIOTECHNOLOGY

Arginase: an emerging key player in the mammalian immune system

(2009) Markus Munder   BRITISH JOURNAL OF PHARMACOLOGY

Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression

(2008) Rita Rotondo et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma

(2008) David J Tate et al.   Journal of Hematology & Oncology

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression

(2008) S. Peter Bak et al.   MOLECULAR IMMUNOLOGY